Evaluating the atittudes of Australian psychologists, psychiatrists and mental health researchers towards 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of PTSD: A double-blind, randomised controlled trial
This double-blind, randomised controlled trial (n=200) aims to evaluate the attitudes of Australian psychologists, psychiatrists, and mental health researchers towards MDMA-assisted psychotherapy for the treatment of PTSD.
Detailed Description
Online, parallel-group randomized vignette study recruiting Australian psychologists, psychiatrists and mental health researchers who read a single vignette describing a hypothetical Phase 3 trial of either MDMA-assisted psychotherapy or a fabricated drug (JB-4801) plus psychotherapy.
Participants complete a ~10-minute survey (one timepoint between February and November 2020) with outcomes including subjective safety concern (10-point Likert) and predicted efficacy (10-point Likert). No direct contact or actual drug administration occurs.
Study Protocol
Preparation
Dosing
Integration
Therapeutic Protocol
Study Arms & Interventions
MDMA vignette
experimentalOnline vignette describing MDMA-assisted psychotherapy (hypothetical Phase 3 trial).
Interventions
- MDMA
Participant reads a vignette describing MDMA-assisted psychotherapy; no actual dosing.
JB-4801 vignette
activeOnline vignette describing a fabricated JB-4801-assisted psychotherapy (control).
Interventions
- Placebo
Fabricated compound 'JB-4801' used in vignette to avoid prior beliefs; no actual dosing.
Participants
Inclusion Criteria
- Participants must be working within Australia as a psychologist, psychiatrist or mental health researcher.
- Psychologists and psychiatrists must be registered with AHPRA.
Exclusion Criteria
- People under the age of 18.
- People who do not work in Australia.
Study Details
- StatusRecruiting
- PhasePhase NA
- Typeinterventional
- DesignRandomizedsingle Blind
- Target Enrollment100 participants
- TimelineStart: 2020-02-11End: 2020-11-02
- Compounds
- Topic